
Oryzon Genomics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Oryzon Genomics S.A.
Access all reports
Oryzon Genomics S.A. is a Spain-based clinical-stage biopharmaceutical company focused on the discovery and development of epigenetic therapies. The company develops small molecule inhibitors targeting specific enzymes involved in gene expression regulation, with therapeutic programs in oncology and neurodegenerative diseases. Oryzon conducts both preclinical and clinical trials and collaborates with academic and industry partners to advance its drug candidates. The company is headquartered in Barcelona, Spain, and its shares are listed on the BME.
Latest articles
)
Adobe: Equipping the Architects of Digital Expression
The story of how Adobe grew from a small garage upstart to one of the largest and most dominant software companies in the world.
21 Mar 2025
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
Ticker symbol
ORY
Country
🇪🇸 Spain